BRAF and melanoma: In advanced-stage previously untreated melanoma patients harboring BRAF exon 15 p.V600 point mutations (p.V600E and p.V600K), such a combination significantly improved PFS (11.0 versus 8.8 months, respectively), OS (25.1 versus 18.7 months, respectively), and overall response rates (69.0% versus 53.0%, respectively) compared with dabrafenib alone [141,142,143,144].